Tropical Medicine Cluster, Chulalongkorn University , Bangkok, Thailand.
Expert Rev Vaccines. 2020 Jun;19(6):499-506. doi: 10.1080/14760584.2020.1775076. Epub 2020 Jun 16.
Dengue infection is the most important mosquito-borne viral disease in the world. Most mosquito control methods currently available for public health use are not very efficacious. Dengue vaccine is required to control dengue diseases in the future through the use of a safe and effective vaccine.
This review covered dengue vaccine development and candidate dengue vaccines in the clinical trial pipeline including licensed dengue vaccine.
Dengue has become an intractable global health problem. Vector control has achieved only limited success in reducing the transmission of dengue. A dengue vaccine is needed as part of an integrated approach to dengue prevention and control since dengue poses a heavy economic cost to the health system and society. Because dengue is a unique and complex disease developing a dengue vaccine has proven equally complex. However, there is an advanced pipeline of vaccine research currently in clinical and preclinical studies including live-attenuated vaccine candidates as well as virus-vectored and virus-like particle-based vaccines.
登革热感染是世界上最重要的蚊媒病毒性疾病。目前可用于公共卫生的大多数蚊虫控制方法效果并不十分有效。未来需要通过使用安全有效的疫苗来控制登革热疾病,因此需要登革热疫苗。
本综述涵盖了登革热疫苗的开发和临床试验中候选登革热疫苗,包括已许可的登革热疫苗。
登革热已成为全球棘手的健康问题。病媒控制在减少登革热传播方面仅取得有限的成功。由于登革热给卫生系统和社会带来沉重的经济成本,因此需要将登革热疫苗作为登革热预防和控制综合方法的一部分。由于登革热是一种独特且复杂的疾病,因此开发登革热疫苗同样复杂。然而,目前有大量处于临床和临床前研究阶段的疫苗研究管道,包括减毒活疫苗候选物以及病毒载体和病毒样颗粒疫苗。